Titan Pharmaceuticals (NSDQ:TTNP) has treated the first patient in a Phase I/II trial of its ropinirole implant designed to treat the signs and symptoms of idiopathic Parkinson’s disease. Ropinirole is a dopamine agonist traditionally given orally to patients with Parkinson’s disease or restless leg syndrome. Titan’s ropinirole implant uses the company’s ProNeura drug delivery tech to […]
Pharmaceuticals
MannKind inks $61m direct offering of common stock
MannKind (NSDQ:MNKD) said today that it inked a deal with a group of unnamed investors for a registered direct offering of 10,166,600 shares of the company’s common stock for $6.00 apiece. The $61 million offering is slated to close later this week. “With this offering, we have made substantial progress in our efforts to recapitalize […]
Study: West’s device aids in dose-sparing administration of polio vaccine
West Pharmaceutical Services (NYSE:WST) touted results today from a study showing that its ID Adapter can improve the intradermal administration of polio vaccines. The study, published in the journal Vaccine, evaluated the feasibility of using a fractional inactivated polio virus vaccine in remote locations where polio outbreaks continue to be of serious concern to public health […]
Catalent launches $450m private offering
Catalent (NYSE:CTLT) said today that its subsidiary, Catalent Pharma Solutions, plans to offer $450 million in senior unsecured notes due 2026. The private offering will be used to fund, in part, the drug-delivery company’s $950 million purchase of biologics manufacturer, Cook Pharmica. The private offering comes on the heels of an underwritten public offering that the […]
pSivida and Nicox partner to develop sustained-release IOP drug for glaucoma patients
pSivida (NSDQ:PSDV) and Nicox (EPA:COX) said today that the companies are collaborating to develop a sustained-release drug to lower intraocular pressure in people with glaucoma or ocular hypertension. The deal combines pSivida’s bioerodible sustained-release drug delivery system with Nicox’s nitric oxide-donating compounds. According to the agreement, pSivida is responsible for initial development activities. Nicox is slated […]
Researchers treat first cancer patients with BTG’s microscopic, drug-loaded beads
Researchers from the UCL Cancer Institute and BTG (LON:BTG) have started the first clinical trial of microscopic beads loaded with a targeted, cancer-fighting drug for patients with primary liver cancer or metastatic colorectal cancer. The trial is designed to evaluate the experimental therapy’s ability to deliver a precise amount of vandetanib directly to the arteries feeding […]
Intersect ENT touts results from pivotal study of steroid-releasing sinus implant
Intersect ENT (NSDQ:XENT) touted data this week from the pivotal Resolve II trial of its investigational steroid-releasing sinus implant, Sinuva. The Phase III trial evaluated Sinuva in 300 adult chronic sinusitis patients, who were all indicated for revision sinus surgery at study entry due to recurrent, medically refractory symptoms and bilateral nasal polyposis. Study participants were […]
Biotronik launches trial to test new coronary drug-eluting stent
Biotronik said yesterday that it began enrolling patients in a trial designed to assess the safety and efficacy of a new coronary drug-eluting stent in de novo coronary artery lesions. The Biovitesse polymer-free device combines ultra-thin struts with a new anti-proliferative limus drug designed to stop excessive cell growth, the company reported. In September, Dr. […]
Insulet looks to lure Animas users
Just days after Johnson & Johnson (NYSE:JNJ) revealed that it plans to shut down its 410-worker Animas insulin pump subsidiary, Insulet (NSDQ:PODD) said it would offer existing Animas insulin pump users a free trial of the company’s Omnipod system. Insulet’s Welcome Program includes a free Omnipod tubeless insulin delivery system, built-in blood glucose meter and 30 days […]
India pulls an about-face on Abbott’s Xience Alpine stent
India’s Department of Pharmaceuticals has stopped Abbott (NYSE:ABT) from pulling its Xience Alpine drug-eluting coronary stent from the market. The move is a reversal from the National Pharmaceutical Pricing Authority’s decision last month to allow Abbott to withdraw the device over a one-year period. Last week, the DoP said it invoked powers described in the Drug […]